^
BIOMARKER:

RAD51C mutation

i
Other names: RAD51C, RAD51 paralog C, R51H3, BROVCA3, RAD51L2
Entrez ID:
Related biomarkers:
Phase 2
Memorial Sloan Kettering Cancer Center
Not yet recruiting
Last update posted :
01/26/2022
Initiation :
02/01/2022
Primary completion :
01/01/2024
Completion :
01/01/2024
HER-2 • PGR • BRCA1 • BRCA2 • RAD51C • RAD51D
|
BRCA1 mutation • BRCA2 mutation • HR positive • HER-2 negative • PALB2 mutation • RAD51D mutation • RAD51C mutation • HR positive + HER-2 negative • RAD51 mutation
|
Keytruda (pembrolizumab) • Lynparza (olaparib)
Phase 2
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
01/19/2022
Initiation :
01/14/2022
Primary completion :
01/01/2024
Completion :
01/01/2024
EGFR • BRCA1 • BRCA2 • HRD • CDK12 • FGFR • RAD51B • BRIP1 • CHEK2 • RAD51C • RAD51D • CHEK1 • RAD54L • BARD1 • FANCL • PPP2R2A
|
BRIP1 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • IDH wild-type
|
Keytruda (pembrolizumab) • Lynparza (olaparib) • temozolomide
Phase 2
Clovis Oncology, Inc.
Recruiting
Last update posted :
01/12/2022
Initiation :
11/21/2019
Primary completion :
12/01/2022
Completion :
03/01/2023
BRCA1 • BRCA2 • RAD51B • BRIP1 • FANCA • RAD51 • RAD51C • RAD51D • BARD1 • NBN
|
BRCA1 mutation • PALB2 mutation • BRIP1 mutation • RAD51D mutation • RAD51C mutation • FANCA mutation • RAD51B mutation • BARD1 mutation • FANCA deletion • NBN mutation • RAD51 mutation
|
Rubraca (rucaparib)
Phase 2
Ohio State University Comprehensive Cancer Center
Not yet recruiting
Last update posted :
12/30/2021
Initiation :
01/01/2022
Primary completion :
12/31/2024
Completion :
12/31/2025
BRCA1 • BRCA2 • RAD51B • BRIP1 • RAD51 • RAD51C • RAD51D • BARD1
|
BRCA1 mutation • PALB2 mutation • BRIP1 mutation • RAD51D mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation
|
Zejula (niraparib)
Phase N/A
Massachusetts General Hospital
Recruiting
Last update posted :
12/15/2021
Initiation :
02/12/2020
Primary completion :
12/01/2030
Completion :
12/01/2040
TP53 • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • BRIP1 • CHEK2 • FANCA • RAD51C • RAD51D • EPCAM • NBN • HOXB13 • GEN1
|
BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • FANCA mutation • PMS2 mutation • NBN mutation
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
12/03/2021
Initiation :
09/20/2021
Primary completion :
03/01/2026
Completion :
03/01/2026
BRCA1 • BRCA2 • HRD • CDK12 • RAD51B • BRIP1 • CHEK2 • RAD51C • RAD51D • BRCA • CHEK1 • RAD54L • BARD1 • FANCL • PPP2R2A
|
BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • CHEK1 mutation • CHEK1 expression
|
Trodelvy (sacituzumab govitecan-hziy) • berzosertib (M6620)
Phase 2
Institut fuer Frauengesundheit
Not yet recruiting
Last update posted :
11/24/2021
Initiation :
01/01/2022
Primary completion :
01/01/2024
Completion :
02/01/2026
HER-2 • PGR • BRCA1 • BRCA2 • ATM • HRD • CHEK2 • RAD51C • RAD51D • BARD1 • XRCC2 • FANCC • SLX4
|
BRCA1 mutation • BRCA2 mutation • HER-2 amplification • HER-2 negative • ATM mutation • HRD • PALB2 mutation • ER positive + PGR positive • PGR positive • RAD51D mutation • CHEK2 mutation • RAD51C mutation • BARD1 mutation • RAD51 mutation
|
Keytruda (pembrolizumab) • Lynparza (olaparib)
Phase 
Sun Yat-sen University
Recruiting
Last update posted :
11/11/2021
Initiation :
10/31/2021
Primary completion :
03/31/2023
Completion :
08/31/2023
BRCA1 • BRCA2 • CDK12 • RAD51B • BRIP1 • CHEK2 • RAD51C • RAD51D • CHEK1 • RAD54L • BARD1 • FANCL • PPP2R2A
|
BRCA1 mutation • BRCA2 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • CHEK1 mutation • CHEK1 expression
Phase 2
Shadia Jalal, MD
Recruiting
Last update posted :
10/26/2021
Initiation :
07/09/2019
Primary completion :
05/01/2022
Completion :
05/01/2023
BRCA1 • BRCA2 • ARID1A • CDK12 • RAD51B • BRIP1 • CHEK2 • FANCA • RAD51 • RAD51C • RAD51D • RAD54L • BARD1 • NBN • GEN1
|
BRCA1 mutation • BRCA2 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • FANCA mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • NBN mutation
|
Zejula (niraparib)
Phase 2
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
09/16/2021
Initiation :
03/07/2019
Primary completion :
02/01/2023
Completion :
02/01/2023
PD-L1 • BRCA1 • BRCA2 • CDK12 • BRIP1 • CHEK2 • FANCA • RAD51C • RAD51D • BARD1
|
BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • FANCA mutation • BARD1 mutation • FANCA deletion
|
Lynparza (olaparib) • Imfinzi (durvalumab)
Phase 1/2
Yonsei University
Not yet recruiting
Last update posted :
08/31/2021
Initiation :
10/01/2021
Primary completion :
12/31/2022
Completion :
05/31/2023
HER-2 • BRCA1 • BRCA2 • HRD • CDK12 • MLH1 • MSH6 • MSH2 • RAD51B • BRIP1 • CHEK2 • RAD51C • RAD51D • CHEK1 • RAD54L • BARD1 • FANCL • PPP2R2A
|
HER-2 positive • BRCA1 mutation • BRCA2 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • CHEK1 expression
|
Keytruda (pembrolizumab) • Lynparza (olaparib) • paclitaxel
Phase 2
Se-Hoon Lee
Recruiting
Last update posted :
08/25/2021
Initiation :
08/23/2021
Primary completion :
12/31/2022
Completion :
12/31/2022
BRCA1 • BRCA2 • SLFN11 • RAD51B • RAD51 • RAD51C • BRCA • RAD50 • RAD54L • RAD52 • RECQL5 • WRN • NBN • RECQL • RECQL4 • RPA1
|
BRCA1 mutation • BRCA2 mutation • RAD51D mutation • RAD51C mutation • RAD51B mutation • MRE11A mutation • RAD50 mutation • RAD54L mutation • BLM mutation • BRCA mutation • NBN mutation • RAD52 mutation • RECQL mutation • RECQL4 mutation • RECQL5 mutation
|
Lynparza (olaparib) • Avastin (bevacizumab)
Phase 2
West Cancer Center
Not yet recruiting
Last update posted :
08/10/2021
Initiation :
08/01/2021
Primary completion :
08/01/2024
Completion :
08/01/2025
BRCA1 • BRCA2 • HRD • CDK12 • RAD51B • BRIP1 • CHEK2 • RAD51C • RAD51D • CHEK1 • RAD54L • BARD1 • FANCL • PPP2R2A • FANCI
|
BRCA1 mutation • ATM mutation • HRD • PALB2 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • HRD + BRCA1 mutation • RAD54L mutation • FANCI mutation • RAD51 mutation
|
Zejula (niraparib) • Jemperli (dostarlimab)
Phase 2
Massachusetts General Hospital
Not yet recruiting
Last update posted :
08/05/2021
Initiation :
01/01/2022
Primary completion :
12/01/2024
Completion :
12/01/2026
BRCA1 • BRCA2 • HRD • BAP1 • RAD51B • BRIP1 • RAD51C • RAD50 • RAD54L • BARD1 • PARP1 • XRCC2 • NBN • XRCC3
|
BRCA1 mutation • ATM mutation • HRD • PALB2 mutation • BAP1 mutation • BRIP1 mutation • RAD51D mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • HRD + BRCA1 mutation • MRE11A mutation • RAD50 mutation • RAD54L mutation • NBN mutation
|
Zejula (niraparib)
Phase 2
Dana-Farber Cancer Institute
Active, not recruiting
Last update posted :
07/02/2021
Initiation :
10/12/2016
Primary completion :
09/30/2020
Completion :
04/01/2022
BRCA1 • BRCA2 • MYC • CCNE1 • FBXW7 • CHEK2 • RAD51C • RAD51D
|
BRCA1 mutation • BRCA2 mutation • ATM mutation • PALB2 mutation • MYC amplification • CCNE1 amplification • FBXW7 mutation • RAD51D mutation • RAD51C mutation • RAD51 mutation
|
prexasertib (LY2606368)
Phase 2
Sidney Kimmel Comprehensive Cancer Center at Jo...
Recruiting
Last update posted :
06/07/2021
Initiation :
03/01/2017
Primary completion :
01/01/2022
Completion :
08/01/2022
BRCA1 • BRCA2 • ATM • CDK12 • RAD51B • BRIP1 • CHEK2 • RAD51C • RAD51D • CHEK1 • BARD1 • FANCL • PPP2R2A
|
BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • CHEK1 expression
|
Lynparza (olaparib)
Phase 2
University Health Network, Toronto
Recruiting
Last update posted :
04/13/2021
Initiation :
07/19/2016
Primary completion :
06/01/2021
Completion :
12/01/2021
BRCA1 • BRCA2 • PALB2 • RAD51B • BRIP1 • RAD51C • RAD51D • MUC16 • BARD1 • PARP1 • FANCM • PPM1D
|
BRCA1 mutation • BRCA2 mutation • PALB2 mutation • BRIP1 mutation • RAD51D mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • FANCM mutation • MUC16 expression • PPM1D mutation • RAD51 mutation
|
Lynparza (olaparib)
Phase 1b/2
Clovis Oncology, Inc.
Active, not recruiting
Last update posted :
04/13/2021
Initiation :
06/28/2019
Primary completion :
10/01/2023
Completion :
03/01/2024
BRCA1 • BRCA2 • RAD51C • RAD51D
|
BRCA1 mutation • BRCA2 mutation • PALB2 mutation • RAD51D mutation • RAD51C mutation • RAD51 mutation
|
Rubraca (rucaparib) • Trodelvy (sacituzumab govitecan-hziy) • lucitanib (E 3810)
Phase 2
Sidney Kimmel Comprehensive Cancer Center at Jo...
Recruiting
Last update posted :
04/12/2021
Initiation :
09/10/2018
Primary completion :
05/01/2022
Completion :
11/01/2022
BRCA1 • BRCA2 • ATM • CHEK2 • FANCA • RAD51C • RAD51D • RAD50 • FANCF • FANCL • FANCI • FANCM • FANCD2 • FANCG • NBN • FANCB • FANCC
|
RAD51D mutation • CHEK2 mutation • RAD51C mutation • FANCA mutation • FANCF mutation • RAD50 mutation • FANCG mutation • FANCI mutation • FANCM mutation • NBN mutation
|
Rubraca (rucaparib)
Phase 2
Sidney Kimmel Comprehensive Cancer Center at Jo...
Recruiting
Last update posted :
03/15/2021
Initiation :
06/03/2019
Primary completion :
03/01/2022
Completion :
03/01/2023
BRCA1 • BRCA2 • BAP1 • CDK12 • RAD51B • BRIP1 • CHEK2 • RAD51C • RAD51D • CHEK1 • RAD54L • BARD1 • FANCL
|
BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • CHEK1 mutation • RAD51 mutation • CHEK1 expression
|
Lynparza (olaparib)
Phase 2
Massachusetts General Hospital
Active, not recruiting
Last update posted :
03/12/2021
Initiation :
01/08/2019
Primary completion :
04/30/2022
Completion :
04/30/2025
BRCA1 • BRCA2 • MYC • ATM • ARID1A • CCNE1 • CDK12 • FBXW7 • ATRX • RAD51B • BRIP1 • CHEK2 • FANCA • RAD51C • RAD51D • BARD1 • FANCF • FANCM • NBN • FANCC
|
BRCA1 mutation • BRCA2 mutation • ATM mutation • ARID1A mutation • MYC amplification • CDK12 mutation • CCNE1 amplification • ATRX mutation • BRIP1 mutation • FBXW7 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • FANCA mutation • RAD51B mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • FANCM mutation • NBN mutation
|
berzosertib (M6620)
Phase 2
Gustave Roussy, Cancer Campus, Grand Paris
Not yet recruiting
Last update posted :
03/03/2021
Initiation :
03/01/2021
Primary completion :
03/01/2024
Completion :
03/01/2027
HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • PBRM1 • CDK12 • BRIP1 • CHEK2 • FANCA • RAD51 • RAD51C • RAD51D • ARID2 • RAD54L • BARD1 • NBN
|
HER-2 positive • HER-2 amplification • DDR • CDK12 mutation • PBRM1 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • FANCA mutation • BARD1 mutation • NBN mutation
|
Zejula (niraparib) • Jemperli (dostarlimab)
Phase 2
Samsung Medical Center
Completed
Last update posted :
02/18/2021
Initiation :
08/01/2016
Primary completion :
01/01/2021
Completion :
01/01/2021
BRCA1 • BRCA2 • ATM • RAD51B • RAD51 • RAD51C • RAD50 • RAD54L • RAD52 • RECQL5 • WRN • NBN • RECQL • RECQL4 • RPA1
|
BRCA1 mutation • BRCA2 mutation • RAD51D mutation • RAD51C mutation • RAD51B mutation • MRE11A mutation • RAD50 mutation • RAD54L mutation • BLM mutation • WRN mutation • NBN mutation • RAD52 mutation • RECQL mutation • RECQL4 mutation • RECQL5 mutation • RPA1 mutation
|
Lynparza (olaparib)
Phase 2
Fudan University
Not yet recruiting
Last update posted :
08/11/2020
Initiation :
09/01/2020
Primary completion :
02/20/2022
Completion :
04/28/2022
HER-2 • BRCA1 • BRCA2 • PTEN • BAP1 • CDK12 • BRIP1 • CHEK2 • FANCA • RAD51C • RAD51D • CHEK1 • RAD50 • BARD1 • FANCF • FANCM • WRN • FANCD2 • NBN • FANCC
|
HER-2 positive • BRCA1 mutation • BRCA2 mutation • HR positive • HER-2 negative • ATM mutation • PALB2 mutation • CDK12 mutation • BAP1 mutation • BRIP1 mutation • CHEK2 mutation • RAD51C mutation • FANCA mutation • BARD1 mutation • FANCF mutation • HR positive + HER-2 negative • MRE11A mutation • RAD50 mutation • BLM mutation • CHEK1 mutation • FANCM mutation • NBN mutation • CHEK1 expression
|
Herceptin (trastuzumab) • cisplatin • Zejula (niraparib) • pucotenlimab (HX008)
Phase 1
M.D. Anderson Cancer Center
Recruiting
Last update posted :
01/31/2020
Initiation :
04/18/2017
Primary completion :
04/18/2021
Completion :
04/18/2022
ER • PGR • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • BRIP1 • RAD51C • RAD51D • BARD1
|
BRCA1 mutation • BRCA2 mutation • PALB2 mutation • BRIP1 mutation • RAD51D mutation • MSH2 mutation • RAD51C mutation • BARD1 mutation • MLH1 mutation • PMS2 mutation • RAD51 mutation